CORE--SOLID TUMOR PHARMACOLOGY

核心--实体瘤药理学

• 批准号: 6654035
• 负责人: CLINTON F STEWART
• 金额: $ 28.58万
• 依托单位: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-06 至 2003-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6654035
• 关键词: DNA topoisomerases; antineoplastics; bioassay; biomedical facility; data collection methodology /evaluation; drug screening /evaluation; enzyme linked immunosorbent assay; genotype; high performance liquid chromatography; histology; liquid chromatography mass spectrometry; microdialysis; neoplasm /cancer pharmacology; pediatric neoplasm /cancer; pharmacokinetics; topotecan; western blottings

DESCRIPTION (provided by applicant): The functions of the Solid Tumor Pharmacology Core are to: A. Perform assays to quantitate drug and drug metabolite concentrations in biological specimens collected from animals and patients as part of preclinical and clinical pharmacokinetic studies within this program. B. Analyze pharmacokinetic data obtained from preclinical and clinical pharmacokinetic studies, and fit appropriate pharmacokinetic and pharmacodynamic models to the data, as requested by investigators in this program. C. Perform genotyping studies on patient samples from clinical trials on Project 6 of this Program. D. Maintain computer databases of data from analyses performed in the Solid Tumor Pharmacology Core, and generate data retrievals and reports as required. E. Perform additional special laboratory procedures as required to support the projects included in this program.

描述（由申请人提供）：实体瘤药理学核心的功能是 A. 进行测定以定量从动物和患者收集的生物样本中的药物和药物代谢物浓度，作为本计划中临床前和临床药代动力学研究的一部分。 B. 按照本计划研究者的要求，分析从临床前和临床药代动力学研究获得的药代动力学数据，并将适当的药代动力学和药效学模型与数据拟合。 C. 对本计划项目 6 临床试验的患者样本进行基因分型研究。 D. 维护实体瘤药理学核心中进行的分析数据的计算机数据库，并根据需要生成数据检索和报告。 E. 根据需要执行额外的特殊实验室程序以支持本计划中包含的项目。